No you conceded hes isnt a bad CEO but a lousy PUBLIC CEO due to his inability to support the stockprice and limited conversation with the public.
He's got a product that's supposedly life and even world-changing and he can't get an institution of any kind to lay down a lousy 100k loan or investment?
Ya thats what the scientific studies say. I'll post it again near the bottom of this post for you to ignore. As to why he cant get quality investment, i do not know? Ive speculated it could be connected to that he will not encumber IP at all and that Sintx has many antitakeover measures in place to prevent hostile takeovers including having CTL setup as a white knight/crown jewels defense. His efforts to protect Sintx IP are extensive and worldwide, but im sure this is also meaningless. Institutions could try to force his hand on the sale of the company before its ready.
I think the clue in his people not buying shares is the fact that Sonny has not, but only since the company went public. Sonny's been CEO for going on 10 years but has been working with Sintx since December 2006 i believe. So thats over 17 years now. While Sintx was a private company called Amedica, Sonny invested about $1.4m in the company over 3 or 4 series rounds. Yet when Sintx went public, he stopped investing and the stockprice/marketcap has continued to drop. All while he has overseen a massive increase in products that could be released to market one day. Him stopping investing once public is odd and yes it could give one pause about Sintx. However when you look at what hes overseen as CEO and then look at the various markets Si3n4 can be used, in mentioned in the scientific study below, it doesnt make sense. Theres some serious value to invest in right there.
Mostly a Spinal company at IPO, Sintx did have a hip product in development. 2016 we found out that a dental implant was being worked on. Now, especially with the coating, Si3n4 could one day be used on just about every type of implant into the human body including Musk's Neuralink implants. That could happen because Sintx, under Sonny's watch, discovered that Si3N4 is antimicrobial. Not just resistant to bacteria colonies, but that it kills them to help prevent them from forming. Not just bacteria, but anti-viral and anti-fungal as well. Si3N4 can kill pretty much any single stranded RNA viruses like COVID and some of the more complex double stranded DNA ones like Herpes. The anti-pathogenic market is not as lucrative as orthopedic but its nothing to scoff at. This didnt exist, as far as i know, until Sonny took over and Dr Giuseppe Pezzotti, whom has done alot of research work for Biomet before it became part of Zimmer Biomet, really began exploring Si3N4. Sonny added Armor division for a less lucrative revenue stream but could one day fund Sintx. He has overseen refinement of its Si3N4 formulation for industrial uses which is why they now have an aerospace contract and R&D efforts for Hypersonics uses. Not overly lucrative but consistent income and better revenue potential than theyve been getting from CTL-Amedica.
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.